Different effects of enoxaparin, nadroparin, and dalteparin on plasma TFPI during hemodialysis: A prospective crossover randomized study

Clinical and Applied Thrombosis/Hemostasis

Volumn 17, Issue 5, 2011, Pages 480-486

  Naumnik, Beata ^a   Rydzewska Rosołowska, Alicja ^a   Myśliwiec, Michał ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

dalteparin; enoxaparin; hemodialysis; nadroparin; prothrombin fragment 1 + 2; tissue factor pathway inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; ENOXAPARIN; NADROPARIN; PLATELET DERIVED GROWTH FACTOR AB; PROTHROMBIN; RECOMBINANT ERYTHROPOIETIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION;

ADULT; AGED; CROSS-OVER STUDIES; DALTEPARIN; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; NADROPARIN; PEPTIDE FRAGMENTS; PLATELET-DERIVED GROWTH FACTOR; PROSPECTIVE STUDIES; PROTHROMBIN; RENAL DIALYSIS;

EID: 80053616433     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029610376936     Document Type: Article

References (16)

1. Fareed J, Hoppensteadt DA, Bick RL. An update on heparins at the beginning of the new millennium. Semin Thromb Hemost. 2000 ; 26 (suppl 1). 5-21
2. Fareed J, Leong WL, Hoppensteadt DA, et al. Generic low-molecular-weight heparins: some practical considerations. Semin Thromb Hemost. 2004 ; 30 (6). 703-713 (Pubitemid 40041606)
3. Brophy DF, Carr ME, Martin EJ, Venitz J, Gehr TW. The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies. J Clin Pharmacol. 2006 ; 46 (8). 887-894 (Pubitemid 44050825)
4. Gouin-Thibault I, Pautas E, Siguret V. Safety profile of different low-molecular weight heparins used at therapeutic dose. Drug Saf. 2005 ; 28 (4). 333-349 (Pubitemid 40545768)
5. Rubin K, Hansson GK, Ronnstrand L, et al. Induction of B-type receptors for platelet-derived growth factor in vascular inflammation: possible implication for development of vascular lesions. Lancet. 1988 ; 1 (8599). 1353-1356
6. Libby P, Warner SJC, Salomon RN, Birinyi LK. Production of platelet-derived growth factor like mitogen by smooth-muscle cells from human atheroma. N Engl J Med. 1988 ; 318 (23). 1493-1498
7. Sagedal S, Hartmann A, Sundstrøm K, Bjørnsen S, Brosstad F. Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant. 2001 ; 16 (5). 987-993 (Pubitemid 32440371)
8. Naumnik B, Borawski J, Myśliwiec M. Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study. Nephrol Dial Transplant. 2003 ; 18 (7). 1376-1382 (Pubitemid 36826960)
9. Polkinghorne KR, McMahon LP, Becker GJ. Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients. Am J Kidney Dis. 2002 ; 40 (5). 990-995 (Pubitemid 35265479)
10. Naumnik B, Borawski J, Pawlak K, Myśliwiec M. Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF-β1 during haemodialysis: a cross-over study. Nephrol Dial Transplant. 2007 ; 22 (6). 1690-1696 (Pubitemid 47073770)
11. Naumnik B, Pawlak K, Myśliwiec M. Different effect of unfractionated heparin and enoxaparin on circulating proangiogenic factors during hemodialysis: a cross-over study. Cytokine. 2007 ; 40 (2). 98-104 (Pubitemid 350180526)
12. Collington F, Frydman A, Caplain H, et al. Comparison of the pharmacokinetics profiles of three low molecular mass heparins-dalteparin, enoxaparin and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost. 1995 ; 73 (4). 630-640
13. Sandset PM, Bendz B, Hansen JB. Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis. 2000 ; 30 (suppl 2). 48-56 (Pubitemid 32234139)
14. Hansen JB, Svensson B, Olsen R, Ezban M, Osterud B, Paulssen RH. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Thromb Haemost. 2000 ; 83 (6). 937-943 (Pubitemid 30411697)
15. Cianciolo G, Stefoni S, Donati G, et al. Intra-and post-dialytic platelet activation and PDGF-AB release: cellulose diacetate vs polysulfone membranes. Nephrol Dial Transplant. 2001 ; 16 (6). 1222-1229 (Pubitemid 32547379)
16. Stefoni S, Cianciolo G, Donati G, et al. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis. Nephron. 2002 ; 92 (3). 589-600